RGC-32 regulates reactive astrocytosis and extracellular matrix deposition in experimental autoimmune...

Area of Science:

• Neuroscience
• Immunology
• Cell Biology

Background:

• Extracellular matrix (ECM) deposition in active multiple sclerosis (MS) lesions can hinder axonal regeneration and alter immune responses.
• The role of Response gene to complement-32 (RGC-32) in gliosis, particularly its involvement in mediating transforming growth factor-beta (TGF-β) downstream effects, remains largely unexplored.

Purpose of the Study:

• To investigate the role of RGC-32 in mediating TGF-β-induced extracellular matrix (ECM) expression and reactive astrocyte markers.
• To determine the impact of RGC-32 on astrogliosis during experimental autoimmune encephalomyelitis (EAE).

Main Methods:

• Primary astrocyte cultures from neonatal rats and RGC-32 knock-out (KO) mice were used to assess TGF-β-induced ECM and α-smooth muscle actin (α-SMA) expression.
• Silencing of RGC-32 and inhibition of Smad3 phosphorylation were employed to evaluate RGC-32's mechanism of action.
• Experimental autoimmune encephalomyelitis (EAE) was induced in RGC-32 KO and wild-type (WT) mice to assess astrocyte phenotype in vivo.

Main Results:

• TGF-β stimulation significantly upregulated collagens I, IV, V, fibronectin, α-SMA, and nestin in rat astrocytes; RGC-32 silencing markedly reduced this expression.
• In RGC-32 KO mice, TGF-β-induced expression of collagens I, IV, V, fibronectin, and α-SMA was significantly lower compared to WT mice.
• SIS3 inhibition of Smad3 phosphorylation reduced RGC-32 nuclear translocation and TGF-β-induced collagen I expression.
• RGC-32 KO astrocytes exhibited an immature, bipolar phenotype, contrasting with the reactive, hypertrophied phenotype of WT astrocytes during EAE.

Conclusions:

• RGC-32 plays a crucial role in mediating TGF-β-induced reactive astrogliosis in the context of EAE.
• RGC-32 is a key mediator of astrocyte activation and ECM production in response to TGF-β signaling.
• RGC-32 emerges as a potential therapeutic target for mitigating reactive astrogliosis in multiple sclerosis.